June 18, 2010, Valencia, Spain

Partner Release:
GILEAD’S HEAD-TO-HEAD STUDY OF CAYSTON® VERSUS TOBRAMYCIN INHALATION SOLUTION IN CYSTIC FIBROSIS PATIENTS ACHIEVES CO-PRIMARY EFFICACY ENDPOINT OF NON-INFERIORITY [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

June 17, 2010, Monmouth Junction, NJ

Partner Release:
Transave, Inc., today reported interim
results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACETM (liposomal amikacin for inhalation). [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

May 24, 2010, Monmouth Junction, NJ

Partner Release:
Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026. [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

May 17, 2010, San Diego, CA

Partner Release:
Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with AeroquinTM (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans. [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

February 23, 2010, Monterey, California

PARI Pharma’s Altera Delivers Gilead’s Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Partner Release:
U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

February 11, 2010, Monterey, California

PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Partner Press Release
Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe

Mon, 08 Feb 2010 - NESS ZIONA, Israel - (Business Wire) Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with
its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency. [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

September 23, 2009, Monterey, California

PARI’s Altera Delivers Gilead’s Cayston, Approved by European Commission to Treat Cystic Fibrosis [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

September 14, 2009, Monterey, California

Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma’s eFlow Technology [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

June 2, 2009, Monterey, California

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

May 20, 2009, Munich, Germany and Monterey, California

PARI Pharma’s Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

May 7, 2009, Munich, Germany and Monterey, California

PARI Pharma Receives 2nd ODD from EMEA; Moves Inhaled Tobramycin – eFlow Technology Program Forward [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

PARI Pharma, New Name of PARI Aerosol Research Institute [more]

January 3, 2007, Monterey, California

PARI’s eFlow Wins Good Design Award [more]

December 4, 2006, Monterey, California

NIH using PARI’s eFlow in HIV/AIDS Vaccine Research [more]

November 29, 2006, Monterey, California

PARI’s eFlow in Cystic Fibrosis Clinical Trial of L-arginine [more]

November 20, 2006, Monterey, California

PARI and Kamada Collaborate to Develop Inhaled Alpha-1 Antitrypsin [more]

October 16, 2006, Monterey, California

PARI’s eFlow Nebulizer used in Alnylam Clinical Trial for Respiratory Syncytial Virus; New Drug Based on RNAi Technology [more]

June 19, 2006, Midlothian, Virginia

PARI Named Leading Nebulizer Company in Cambridge Consulting Survey; Market Dominance Also Visible with Frost & Sullivan Award for Product Innovation [more]

May 17, 2006, Midlothian, Virginia

PARI Celebrates 100 Years of Aerosol Therapy [more]

April 10, 2006. Monterey, California

PARI Pharma receives Medical Design Excellence Award for eFlow Nebulizer [more]

April 6, 2006. Gemünden and Munich, Germany

Activaero and PARI combine technologies to create controlled breath nebulizer [more]

April 6, 2006.  Biotech Business Week

Related Kamada Press Release [more]

January 24, 2006. Monterey, California

PARI Pharma and Kamada to develop Inhaled Emphysema Therapy [more]

November 15, 2005. Monterey, California

PARI to present eFlow Development at Medical Plastics Seminar; Discussion of a Customizable Platform for New Inhaled Drug Formulations [more]

November 14, 2005. Monterey, California

PARI Issued US Patent for eFlow; Device Innovations Lead to Greater Efficiency in Drug Delivery [more]

July 29, 2005. Munich, Germany

PARI’s Inhaled Cyclosporin Granted Orphan Status in EU  [more]

October 20, 2004. Monterey, California

PARI Pharma’s Formulation Work and eFlow Featured in Corus Pharma’s Positive Phase II Trial Results -- Marks Greater Headway in Drug/Device Matching [more]

August 23, 2004. Monterey, California

PARI Granted Orphan Drug Designation for Inhaled Cyclosporine – Potential New Therapy for Lung Transplant Patients [more]

April 25, 2004. Monterey, California

Corus Pharma’s Phase III Trial for Cystic Fibrosis Drug is First to Feature PARI’s eFlow -- Marks Customization in Drug/Device Matching [more]